ROCCHETTI MARCELLA

Vinarsky, V., Pagliari, S., Aldabash, B., Martino, F., Mazzotti, C., Jirakova, K., et al. (2025). YAP1 reactivation in cardiomyocytes following ECM remodelling contributes to the development of contractile force and sarcomere maturation. CELL DEATH DISCOVERY, 11(1) [10.1038/s41420-025-02793-2]. Detail

Zaza, A., Rocchetti, M. (2025). Development of Small-molecule SERCA2a Stimulators: A Novel Class of Ino-lusitropic Agents. EUROPEAN CARDIOLOGY, 20 [10.15420/ecr.2024.52]. Detail

Frosio, A., Marchese, P., Bertoli, G., Molla, D., Arici, M., Bartolucci, C., et al. (2025). Hypokalemia and bradycardia unmask the loss-of-function phenotype of a Brugada Syndrome SCN5A mutation. EUROPACE [10.1093/europace/euaf160]. Detail

Molla, D., Frosio, A., Bertoli, G., Piantoni, C., Arici, M., Bartolucci, C., et al. (2024). In-vitro studies of the NaV1.5 S805L Brugada mutation: The resting cell voltage is a critical element in determining the pathological or physiological phenotype of the current. Intervento presentato a: XXIV congress of the italian society of cardiovascular research, Imola, Italy [10.1016/j.vph.2024.107337]. Detail

Arici, M., Hsu, S., Ferrandi, M., Barassi, P., Ronchi, C., Torre, E., et al. (2024). Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment. Intervento presentato a: XXIV Congress of the italian society of cardiovascular research, Imola, Italy [10.1016/j.vph.2024.107295]. Detail